CHEMRING GROUP PLC (CHG) — Investment Research Note

Executive summary

Chemring is a UK-headquartered defence technology group operating in two segments — Countermeasures & Energetics (high-grade military explosives, propellants, decoy flares, precision initiators for missiles/space) and Sensors & Information (Roke, a cyber/EW/AI consulting-and-products business; plus US biological detection sensors). Across the five-year period revenue has grown from ~£393m (FY21) to £497m (FY25) with the order book nearly tripling to £1.4bn, driven by post-Ukraine European rearmament, NATO stockpile replenishment and sustained US space/missile demand; underlying operating margin stepped up from 14.6% to 14.8% while the group executed a £200m energetics capacity expansion co-funded by ~£90m of grants. The single most important valuation point today is that the stock trades on ~26x trailing EPS with H1 2026 margins and EPS already compressing (op margin 10.3%, EPS -8%) — the capex-driven step-up to +£100m revenue / +£30m operating profit from 2028 is the required catalyst to justify the current rating.

Fair value estimate

• Fair value range: 420p – 500p per share (implied market cap £1,137m – £1,353m)
• Methodology: blended forward P/E on FY27E underlying EPS and a sum-of-parts cross-check.
  • FY27E underlying EPS ~22–25p (modelling mid-single-digit revenue growth, operating margin recovering to ~15% as Scotland/Chicago/Norway capacity ramps, offsetting ~£3m higher interest on peak net debt).
  • Core P/E range 18–20x (defence-tech premium but tempered by capex-funding net debt rise to ~£200m+ and FY26 margin dip).
  • Cross-check SOTP: Roke on 2.0–2.5x FY27E revenue (£220m) = £440–550m; C&E on 10–11x FY27E operating profit (~£80m) = £800–880m; less net debt ~£180m → equity value £1,060–1,250m.
• Vs. current £1,382.5m market cap: downside of ~11% to ~18% (mid-point 460p → -11%).
• The stock is fairly-to-fully valued; the H1 2026 margin reset and higher-for-longer peak net debt argue against paying for the FY28 bull case today.

Sector context

• ICB classification confirmed: Industrials / Industrial Goods & Services — specifically defence equipment and specialty chemicals.
• Chemring's quality profile is above-average for the sector: better order visibility (84% of FY27E C&E revenue already covered), differentiated niches with high regulatory barriers (energetics licensing), and modest leverage. Growth is above typical UK industrials; operating margins mid-teens are mid-range for diversified defence.
• Listed peers: QinetiQ Group (defence tech services, closest Roke analogue), Babcock International (defence engineering/support), BAE Systems (larger scale platform defence). Chemring trades at a premium to QinetiQ (~15x) and in line with BAE (~22–25x).

Investment thesis

1. Structural rearmament tailwind with 2.8x revenue cover in the order book. Record £1.4bn backlog at H1 2026 provides visibility through 2028; management explicitly cites "81% cover of expected 2027 revenue and 68% of 2028" in C&E, underpinning the capex payback 2026-06 interim.
2. Energetics capacity expansion delivers quantified operating leverage. The ~£200m programme (net £110m after grants) across Chicago, Scotland and Norway is projected to add £100m p.a. revenue and £30m p.a. operating profit from 2028 — ~30% incremental margin, roughly double the current segment margin 2026-06 interim; 2025-06 interim.
3. Roke is a credible, if indirect, AI-cycle beneficiary with embedded operating leverage. CORTEXA counter-drone product launched April 2026 with early sales in Sweden/UK; Vigil AI CSAM-detection platform scaling via Resolver channel; £300m+ international pipeline; capacity being held for sizeable upcoming awards, implying strong incremental drop-through when utilisation normalises 2026-06 interim.

Key risks

1. Peak-capex balance sheet strain and FY26 margin reset. Net debt rose from £89m to £144.5m in H1 2026 (1.47x EBITDA, up from 0.98x) with management guiding further rises through FY26–27 before new capacity comes online; H1 2026 underlying op margin dropped to 10.3% from 11.9% 2026-06 interim.
2. UK Defence Investment Plan delays and ASC/Alloy closure. Delayed UK DIP has pushed Roke contracts right; ASC decoy business closed with £6.7m impairment and £8.1m discontinued-ops loss, demonstrating that even "sole-source" defence franchises can lose demand overnight 2026-06 interim; 2025-11 trading update legacy.
3. Capex execution and timeline risk. The Scotland propellants plant and Norway Phase 2 are still commissioning/under construction; any slippage pushes the £30m incremental profit beyond 2028 and leaves current valuation unsupported 2026-06 interim; 2024-06 interim.

Operating leverage

Chemring's leverage profile is clearer than typical diversified industrials but not pure fixed-cost. The C&E segment is capex-heavy with high process-safety-driven overhead: FY25 segmental EBITDA margin was ~25%, and the stated economics of the capacity expansion — £100m additional revenue generating £30m additional operating profit — translate to a ~30% incremental contribution margin, materially above the current ~19% segment margin. In Sensors & Information, Roke is a people-plus-platform business where H1 2026 margins compressed to 10.1% (from 17.4%) specifically because management maintained headcount and cleared staff "in anticipation of pipeline opportunities" — an explicit statement that fixed costs are being carried through a utilisation dip, so each incremental £10m of revenue above plan should drop through at 25–35% 2026-06 interim. Group unallocated costs (£19.3m FY25) are modest fixed overhead. A 10–20% group revenue beat above the FY27 plan plausibly adds 25–40% to operating profit — meaningful but not SaaS-like multiples.

Value-trap signals

• H1 2026 statutory operating profit down 25% YoY and underlying EPS -8%; successive non-underlying charges (ASC impairment £6.7m, pension buy-in costs, acquisition-related IFRS 2 charges) are becoming a recurring feature of the P&L.
• Net debt trajectory worsening — up from £14.4m at FY23 to £144.5m at H1 2026 — and management flags further rises before capex-driven recovery.
• Dependency on US DoD orders remains lumpy (continuing resolutions in 2022, Alloy demand collapse in 2025, HMDS transition to sustainment in 2024).
• Repeated use of "non-underlying" exceptional treatment (pension, restructuring, impairments) widens the gap between underlying and statutory EPS.

Earnings vs. expectations

Across the filings reviewed, Chemring has consistently guided conservatively and delivered in line rather than beating:

• FY22, FY23, FY24, FY25 all delivered "in line with Board expectations" with explicit reference to analyst consensus (FY23 consensus £66.9m → delivered £69.2m underlying operating profit; FY24 consensus mid-point ~£72m → delivered £71.1m) 2023-09 trading update; 2024-10 trading update.
• Specific misses/warnings: FY22 operational issues at Tennessee countermeasures (adverse weather, automation ramp delays); FY23 non-cash impairments on AVCAD/EHD/HMDS of £49m; FY25 Alloy wind-down.
• H1 2026 confirmed FY26 expectations unchanged but with 70% H2 weighting — a demanding back-end-loaded year.
• Overall pattern: predominantly meets, occasional operational misses offset by order-intake beats; no track record of material consensus beats.

Conviction

4 — high.

Anchors: (a) exceptionally well-disclosed order book with explicit year-by-year coverage figures; (b) quantified capex payback (£100m revenue / £30m operating profit by 2028) that is contractually underpinned by named frameworks like Diehl Defence €231m, SAAB £36m, STORM £251m; (c) multiple converging valuation approaches (P/E, SOTP, order-book-to-market-cap) all land in the £1.1–1.35bn range.

Caveats: (1) a material swing factor is Roke's margin recovery, which depends on UK DIP publication timing — a political/customer variable rather than operational; (2) peak net debt and 2027/28 capex timing uncertain, so FY27 EPS has a wide error bar.

Driver scoring rationale (summary)

• AI beneficiary (45): Roke has genuine AI/ML products (CORTEXA, Vigil AI, geospatial intelligence) but it's ~35% of group revenue; the dominant group driver is the defence rearmament cycle, not AI-infrastructure spend. Not a picks-and-shovels AI play.
• Operating leverage (60): Clearly quantified 30% incremental margins from capex; Roke under-utilisation currently masks fixed-cost carry. Significant but not SaaS-like.
• Earnings surprise trend (50): Pattern is "meets," not beats.
• Cyclicality (45): Defence spending has shifted to structural uptrend; order book provides visibility, but still subject to government budget timing.
• Moat (65): High barriers to entry in licensed energetics manufacture, sole-source positions on multiple US programs (EMBD, JBTDS, Artemis initiators), long-term framework contracts.
• Leverage (45): Net debt rising to peak ~2x EBITDA; manageable within 3x covenant but trending upward during peak capex.
• Earnings quality (55): Repeated non-underlying adjustments, deferred-consideration IFRS 2 charges, and discontinued operations reduce clarity; cash conversion typically healthy (~100% rolling average) but H1 2026 at 42%.
• Management quality (65): Michael Ord has executed well on strategy, disciplined M&A (Cubica, Geollect, Landguard, Vigil AI are small bolt-ons), progressive dividend, £40m buyback. ASC strategic review handled transparently.
• Growth momentum (60): Mid-single-digit revenue growth with step-up expected post-2028; H1 2026 profit declining is a near-term headwind.

Overall score

480 / 1000. Chemring is a quality mid-cap defence industrial with real operating leverage and a genuine, if partial, AI angle via Roke. However, three factors keep it out of the strong-buy band for this investor: (1) the AI exposure is indirect — ~35% of revenue, embedded in a broader defence franchise — rather than being a picks-and-shovels AI buildout play; (2) at 26x trailing earnings with margins compressing in the near term, the valuation already prices in the 2028 capex payoff rather than offering it as upside; (3) peak capex and rising net debt reduce the downside-protection quality that would otherwise lift this into the 600+ band. A better entry point ~400–450p would materially change the attractiveness.